Houm Plant Extract (Ephedra), An Iranian Traditional Remedy for Insulin Resistance

  • Elham Ehrampoush
  • Amin Koohpayeh
  • Noushid Zare
  • Layla Shojaie
  • Reza Homayounfar
  • Amin Almasi
  • Saied Taghizade
  • Reza Alipoor
Keywords: Ephedra, insulin resistance, cholesterol, rat

Abstract

Objectives: Houm plant (ephedra) extract for many years has been used in traditional Iranian medicine for the treatment of heart problems and diabetes. The objective of this study was to determine the short- and long-term effects of this extract on weight, lipid profile, and insulin sensitivity. Material and Method: In a randomized experimental study five groups of rats received high- calorie and high-fat diet, with 416 calorie energy per 100 grams. For three groups, Houm extract of 5, 30, and 100 mg was started at the end of the 4th week in the form of gavage feeding, while 150 mg of Houm extract was given to one group in the form of acute dose. One of the groups received high-calorie and high-fat diet without intervention, while another group was the control group. Results: Receiving Houm extract at 5, 30, and 100 mg dose reduced the weight gain trend, while 150 mg of Houm extract reduced weight compared to high energy diet (306.00±57.34 vs. 348.00±43.73 P.value<0.05). 5 and 30 mg groups did not cause significant changes in lipid profile, blood sugar, and insulin. Further, 100 mg dose of Houm extract reduced the cholesterol level (56.40±6.50 vs. 63.54±8.39; P.value<0.05) and the insulin level (2.78±1.19 vs. 3.90±1.45 P.value<0.05). The acute dose of 150 mg of Houm significantly reduced cholesterol, triglyceride, and HDL levels. In this group, insulin significantly decreased (2.66±0.63 vs. 3.90±1.45 P.value<0.05). Conclusions: Houm extract could be used as a supplement to optimize lipid profile, sensitize tissues to insulin, and reduce weight in emergency cases.

References

Babai, M.A., et al., Defining a BMI cut-off point for the Iranian population: the Shiraz Heart Study. PLoS One, 2016. 11: p. e0160639.

Despres, J., Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. Journal of endocrinological investigation, 2006; 29: 77.

Zand, H., et al., Obesity-induced p53 activation in insulin-dependent and independent tissues is inhibited by beta-adrenergic agonist in diet-induced obese rats. Life sciences, 2016; 147: 103-9.

Stafford, R.S., et al., National patterns of physician activities related to obesity management. Archives of family medicine, 2000; 9: 631.

Wadden, T.A., et al., Obese women's perceptions of their physicians' weight management attitudes and practices. Archives of family medicine, 2000; 9: 854-62.

Homayounfar, R., et al., Relationship of p53 accumulation in peripheral tissues of high-fat diet-induced obese rats with decrease in metabolic and oncogenic signaling of insulin. General and comparative endocrinology, 2015; 214:134-9.

Márquez, F., et al., Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Critical reviews in food science and nutrition, 2012; 52: 585-94.

Shekelle, P.G., et al., Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. Jama, 2003; 289: 1537-45.

Kim, B.-S., M.-y. Song, and H. Kim, The anti-obesity effect of Ephedra sinica through modulation of gut microbiota in obese Korean women. Journal of ethnopharmacology, 2014; 152: 532-9.

Yen, M. and M.B. Ewald, Toxicity of weight loss agents. Journal of medical toxicology, 2012; 8: 145-52.

Ehrampoush, E., et al., Ability of dairy fat in inducing metabolic syndrome in rats. SpringerPlus, 2016; 5: 2020.

Bent, S., et al., The relative safety of ephedra compared with other herbal products. Annals of internal medicine, 2003; 138: 468-71.

Rotblatt, M., Herbal medicine: expanded commission E monographs. Annals of internal medicine, 2000; 133: 487-87.

Hackman, R., et al., Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. International journal of obesity, 2006; 30: 1545-56.

Hirsch, J., R.M. Mackintosh, and L.J. Aronne, The Effects of Drugs Used to Treat Obesity on the Autonomic Nervous System&ast. Obesity, 2000; 8:227-33.

Krentz, A., K. Fujioka, and M. Hompesch, Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles. Diabetes, Obesity and Metabolism, 2016; 18: 558-70.

Patel, D.K. and F.C. Stanford, Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgraduate medicine, 2018; 130: 173-82.

Vukovich, M.D., et al., Caffeine–herbal ephedra combination increases resting energy expenditure, heart rate and blood pressure. Clinical and experimental pharmacology and physiology, 2005; 32: 47-53.

Greenway, F.L., et al., Effect of a Dietary Herbal Supplement Containing Caffeine and Ephedra on Weight, Metabolic Rate, and Body Composition&ast; &ast. Obesity, 2004; 12: 1152-7.

Astrup, A., et al., The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism, 1992; 41: 686-8.

Boozer, C., et al., Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity, 2002; 26: 593.

Kalman, D.S., et al., Effects of a weight-loss aid in healthy overweight adults: double-blind, placebo-controlled clinical trial. Current Therapeutic Research, 2000; 61:199-205.

Malecka-Tendera, E., Effect of ephedrine and theophylline on weight loss, resting energy expenditure and lipoprotein lipase activity in obese over-fed rats. International journal of obesity, 1993; 17: 343-7.

Published
2019-03-25
Section
Original Research